Exclusive Summary

• Backed by US-FDA GMP certification and US market registration, enabling fast-track regulatory approvals in ROW markets (LATAM, MENA, SEA) strictly relying on SRA (Strict Regulatory Authority) reference.
• Offers a comprehensive range of strengths (12.5mg, 25mg, 37.5mg, 50mg), perfectly addressing the real-world clinical necessity for frequent dose titration in RCC and GIST patients.
• Capitalizes on the post-patent landscape with exceptional supply-chain cost efficiencies from China, securing a strong competitive edge in national tenders and institutional procurement globally.
• Continues to be a WHO Essential Medicine (EML), securing persistent baseline demand as an affordable, standard-of-care front-line targeted therapy for RCC in emerging and developing markets.